Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

2.230 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Lexaria Bioscience (NASDAQ: LEXX) Optimistic of Positive Study Results
Via Investor Brand Network
As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
Via Investor Brand Network
Lexaria Optimistic About Expanded DehydraTECH Investigations
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking... 
Via Benzinga
Lexaria (NASDAQ: LEXX) Optimistic About Expanded DehydraTECH Investigations
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
Via Investor Brand Network
Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
Photo by Shelby Ireland on Unsplash 
Via Benzinga
Lexaria (NASDAQ: LEXX) World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
Via Investor Brand Network
Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be... 
Via Benzinga
Following Sildenafil Study, Lexaria (NASDAQ: LEXX) Announces Plans for More Studies in 2022
Via Investor Brand Network
Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022
Via Investor Brand Network
Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated as Treatment for Multiple Conditions
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
Via CannabisNewsWire
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-... 
Via Benzinga
Lexaria (NASDAQ: LEXX) Technology Shows Promise in Improving Performance of ED Drugs
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs
Via Investor Brand Network
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating... 
Via Benzinga
Lexaria (NASDAQ: LEXX) CEO Summarizes 2021 Milestones in Letter to Shareholders
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Summarizes 2021 Milestones, Outlines 2022 Plans and Expectations, in Annual Letter to Shareholders
Via Investor Brand Network
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study
Via Investor Brand Network
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the... 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.